Tyrosine Kinase Inhibitor (TKI)
Patients harboring EGFR mutation after primary resistance to crizotinib and response to EGFR-tyrosine kinase inhibitor
... EGFR-tyrosine kinase inhibitor (EGFR-TKI) that has shown effectiveness as therapy for advanced NSCLC with EGFR activating mutations, such as erlotinib and ...
5
Ibrutinib, a Bruton’s tyrosine kinase inhibitor, exhibits antitumoral activity and induces autophagy in glioblastoma
... mTOR kinase inhibi- tors, promoted GBM cell death by inducing apoptosis ...mTOR inhibitor, NVPBEZ235, with CQ induced apoptosis of glioma cells ...with Tyrosine Kinase Inhibitor (TKI), ...
13
Tyrosine kinase inhibitor NVP BGJ398 functionally improves FGFR3 related dwarfism in mouse model
... mechanism of action in the growth plate needs to be elucidated. However, the most direct therapeutic strategy would be to coun- teract the hyperactivity of FGFR3 using a tyrosine kinase inhibitor ...
15
All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to Ponatinib
... of tyrosine kinase inhibitor (TKI) therapy has considerably improved the survival of patients suffering chronic myelogenous leukemia ...to kinase domain mutations can be generally circumvented ...
9
Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development
... Nevertheless, considering the unsatisfactory efficacies and limitations of current therapies for the different stages of many cancers, there is still a need to develop innovative, more effective, and safer anticancer ...
11
ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside
... receptor tyrosine kinase inhibitor is a potent inhibitor of members of the vascular endothelial growth factor (VEGF) and platelet derived growth factor (PDGF) receptor ...
13
Herbimycin A, a pp60c src tyrosine kinase inhibitor, inhibits osteoclastic bone resorption in vitro and hypercalcemia in vivo
... pp60c-src tyrosine kinase is required and essential for osteoclastic bone resorption, we tested the effects of the antibiotic herbimycin A, which is an inhibitor of pp60c-src on osteoclastic bone ...
6
Review of current classification, molecular alterations, and tyrosine kinase inhibitor therapies in myeloproliferative disorders with hypereosinophilia
... rearrangements, tyrosine kinase inhibitors at low dose induce rapid and complete hematological remission in the majority of these ...Other kinase inhibitors are ...of tyrosine kinase ...
11
A mathematical model separates quantitatively the cytostatic and cytotoxic effects of a HER2 tyrosine kinase inhibitor
... Background: Oncogene signaling is known to deregulate cell proliferation resulting in uncontrolled growth and cellular transformation. Gene amplification and/or somatic mutations of the HER2/Neu (ErbB2) proto-oncogene ...
11
<p>Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies</p>
... non-receptor tyrosine kinases, which ultimately lead to the mediation of key tumor- driven ...Several tyrosine kinases (ie, EGFR, FGFR, PDGFR, VEGFR), are aberrantly activated in most common tumors, ...
11
The effects of ponatinib, a multi-targeted tyrosine kinase inhibitor, against human U87 malignant glioblastoma cells
... receptor tyrosine kinases contributes to pathological development of ...targeting tyrosine kinase receptors have poor therapeutic ...multi-targeted tyrosine kinase inhibitor, on ...
7
Clinical response to sunitinib as a multitargeted tyrosine-kinase inhibitor (TKI) in solid cancers: a review of clinical trials
... titargeted tyrosine-kinase inhibitor that blocks activation through the stem cell-factor receptor (Kit) and platelet-derived growth-factor ...
10
Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged nonsmall cell lung cancer and beyond
... (EGFR) tyrosine inhibitors were first approved for the treatment of non-small cell lung cancer (NSCLC) in 2003 in the ...lymphoma kinase (ALK) rearrangement in NSCLC in 2007 by two independent groups not ...
15
The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients
... receptor tyrosine kinase inhibitors (EGFR TKI) produces dramatic response and favorable prognosis in patients with lung adenocarcinoma harboring epidermal growth factor receptor (EGFR) mutations, especially ...
10
Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells
... fusion kinase Bcr-Abl. Bcr-Abl tyrosine kinase inhibitors (TKIs), such as imatinib mesylate (IM), revolutionized CML ...Bcr-Abl kinase domain or by aberrant signaling by its effectors, ...
7
Intestinal epithelial potassium channels and CFTR chloride channels activated in ErbB tyrosine kinase inhibitor diarrhea
... ErbB tyrosine kinase inhibitors (TKIs) are used for the treatment of a variety of cancers that overexpress ErbB receptors, including breast cancer, non-small cell lung cancer, and head and neck ...
15
Direct activation of PP2A for the treatment of tyrosine kinase inhibitor–resistant lung adenocarcinoma
... combination of MK2206 (6 mg/kg) and AZD6244 (24 mg/kg), or SMAP DT-061 (5 mg/kg). MK2206 and AZD6244 are kinase inhibitors that inhibit AKT and MEK, respectively. A combination of these 2 agents would lead to the ...
12
Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma
... TKI inhibitor PF-2341066 alone, or in combination with cisplatin, was investigated for its ability to block HGF-induced signaling and biological effects in vitro and in ...TKI inhibitor, PF-2341066, ...
11
Synergistic anticancer effects of combined γ-tocotrienol with statin or receptor tyrosine kinase inhibitor treatment
... receptor tyrosine kinase inhibi- tors synergistically inhibits the mammary tumor cell growth by inhibiting the activation of multiple EGF receptor family members and subsequently suppressing EGF-dependent ...
12
Case Report Treating pulmonary blastoma with EGFR tyrosine kinase inhibitor - a rare case report
... Abstract: Pulmonary blastoma (PB) is a rare primary lung malignancy, comprising 0.25-0.5% of all primary lung tu- mors. This article reports a 60-year-old female patient with PB, who presented progressive dyspnea with ...
6